Dr. Shaw is currently CEO and President of a new start up, Vedantra Pharmaceuticals, headquartered in Cambridge, Massachusetts. Vedantra is a spinout from MIT working on a vaccine delivery platform. Before Vedantra, Dr. Shaw was the Chairman of the Board and Chief Science Officer of Vaxinnate Corporation. He joined Vaxinnate from the Merk Vaccine Research Division where he was Executive Director of MVD’s Public Policy, Public Health and Medical Affairs Department. Prior to this, he wsa the Executive Director of Virus & Cell Biology at Merk Research Laboratories, responsible for all the aspects of live virus vaccine research, as well as technical aspects of development and production. His responsibilities covered research and early development of recombinant protein-based vaccines. Dr. Shaw was instrumental in the development of a combination measles-mumps-rubella-varicella vaccine (Zostavax®) as well as numerous early-stage experimental vaccines. He has over 15 years of experience in the development, testing manufacturing, and Plasmodium falciparum as well as cytokines, cell trafficking and natural inhibitors of inteleukin-1 at Biogen, SA in Geneva, Switzerland.